J&J'S $1 BIL ACQUISITION OF KODAK CLINICAL DIAGNOSTICS DIVISION
This article was originally published in The Gray Sheet
Executive SummaryJ&J'S $1 BIL ACQUISITION OF KODAK CLINICAL DIAGNOSTICS DIVISION gives the company three product lines in the clinical chemistry and immunodiagnostic areas to complement its existing diagnostic business. The companies announced an agreement Sept. 6 under which Johnson & Johnson would pay $1.008 bil. for all the technology, production equipment, products, and roughly 450 patents of Kodak's Clinical Diagnostics business. Kodak's 2,800 employees worldwide, including a U.S. sales force of about 200, will become employees of J&J.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.